Grifols A : Credit metrics therapy
Grifols’ operating performance should continue to improve in H2 2023 and in 2024 owing to the ongoing recovery of plasma collection volumes and its € 450m savings plan that comprises efficiency measures as well as a lower donor costs. The plan was fully implemented in H1 2023 and its impact will be mostly seen in the P&L in H2 2023 and in 2024 (forecasts of € 85m and € 290m respectively). It should more than offset the impact of inflation and help the EBITDA margin (excluding Bio...Grifols is engaged in developing, manufacturing and distributing a range of plasma derivative products. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend the lives of individuals who suffer from chronic and acute conditions. Co. also specializes in providing infusion solutions, nutrition products, medical devices, diagnostic instrumentation and reagents for use in hospitals and clinics. Co.'s products and services are used by healthcare providers in approximately 100 countries. Co.'s business is organized into three divisions: Bioscience, Diagnostic, Hospital and Raw Materials.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.